Fed Governor Cook sues Trump over firing attempt
Introduction & Market Context
Sage Therapeutics (NASDAQ:SAGE) presented its first quarter 2025 financial results on April 29, highlighting the company’s continued focus on its postpartum depression (PPD (NASDAQ:PPD)) treatment ZURZUVAE. The biopharmaceutical company’s stock closed at $7.77 on the day of the presentation, near the lower end of its 52-week range of $4.62-$14.56, reflecting ongoing investor concerns about the company’s path to profitability.
The presentation, led by CEO Barry Greene, COO Chris Benecchi, and CSO Mike Quirk, outlined Sage’s core priorities for 2025 while showcasing the commercial progress of ZURZUVAE in what the company describes as a "highly promotionally responsive PPD market."
Quarterly Performance Highlights
Sage reported significant traction for ZURZUVAE in the PPD market, with over 3,000 shipments made to women with PPD in Q1 2025. The company noted that approximately 80% of prescriptions were written by OBGYNs, and more than 70% of women prescribed ZURZUVAE received it as their first new treatment for PPD, suggesting strong initial positioning in the treatment paradigm.
The company’s presentation highlighted these achievements with visual evidence of the product’s market presence:
Despite the impressive shipment numbers, Sage’s financial results revealed a more complex picture. The company reported total revenue of $14.1 million for Q1 2025, compared to $7.9 million in Q1 2024. However, this increase was driven entirely by collaboration revenue, which rose to $13.8 million from $6.2 million in the prior-year period.
Detailed Financial Analysis
The financial results slide revealed a concerning trend in product revenue, which fell to $0.0 million in Q1 2025 from $1.7 million in Q1 2024. This stark contrast between increased shipments and zero product revenue raises questions about the company’s revenue recognition policies, potential distribution partnerships, or possible promotional pricing strategies.
On a more positive note, Sage significantly reduced its net loss to $62.2 million in Q1 2025, compared to $108.5 million in Q1 2024. This improvement was largely driven by a dramatic decrease in R&D expenses, which fell to $22.8 million from $71.7 million in the prior-year period, likely reflecting the company’s shift toward commercialization rather than early-stage research.
The complete financial picture is illustrated in the following slide:
Sage’s cash position continued to decline, with cash and marketable securities totaling $0.4 billion at the end of Q1 2025, down from $0.7 billion a year earlier. This represents a significant reduction from the $647 million reported in Q2 2024, raising potential concerns about the company’s burn rate as it invests in commercialization efforts.
Strategic Initiatives
Sage outlined several commercialization initiatives for 2025, focusing on expanding its reach and awareness in the PPD market. These include joint salesforce expansion to reach more healthcare providers, building on ZURZUVAE branded media, expanding social media influencer campaigns, and increasing investment in disease state awareness to support improved PPD screening and diagnosis.
The following slide details these initiatives with visual examples of the company’s marketing efforts:
The company also presented its current pipeline, which includes marketed ZURZUVAE for PPD, SAGE-319 in Phase 1 for behavioral symptoms associated with neurodevelopmental disorders, pre-clinical candidates SAGE-817 and SAGE-039 for neurodevelopmental disorders, and SAGE-324 listed as Phase 2 ready for seizures in developmental and epileptic encephalopathies.
Notably, the inclusion of SAGE-324 as Phase 2 ready appears to contradict information from the company’s Q2 2024 earnings, which mentioned the discontinuation of this program due to negative results. This discrepancy was not addressed in the presentation materials.
Forward-Looking Statements
Sage’s core priorities for 2025 center around three key areas: continued commercial momentum for ZURZUVAE, targeted pipeline development in neurodevelopmental disorders and neuropsychiatry, and financial focus. The company aims to optimize ZURZUVAE commercialization in PPD while prioritizing pipeline programs, decreasing operating expenses, and exploring business development opportunities.
The management team, including CEO Barry Greene, COO Chris Benecchi, and CSO Mike Quirk, emphasized their commitment to these priorities during the presentation:
While Sage has made progress in reducing its net loss and increasing shipments of ZURZUVAE, the company faces significant challenges ahead. The disconnect between shipment numbers and product revenue will likely be a key focus for investors and analysts in the coming quarters, as will the company’s declining cash position and its ability to achieve sustainable growth in the competitive neuroscience therapeutics market.
As Sage continues its transition from a research-focused organization to a commercial-stage company, its ability to translate ZURZUVAE’s apparent clinical adoption into meaningful revenue will be critical to its long-term success and financial stability.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.